Read-Gene Statistics

Total Valuation

Read-Gene has a market cap or net worth of PLN 62.72 million. The enterprise value is 65.34 million.

Market Cap	62.72M
Enterprise Value	65.34M

Important Dates

The last earnings date was Tuesday, November 11, 2025.

Earnings Date	Nov 11, 2025
Ex-Dividend Date	n/a

Share Statistics

Read-Gene has 11.79 million shares outstanding.

Current Share Class	1.49M
Shares Outstanding	11.79M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	7.16%
Owned by Institutions (%)	n/a
Float	1.27M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	4.13
PB Ratio	23.41
P/TBV Ratio	23.41
P/FCF Ratio	41.05
P/OCF Ratio	31.66
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-73.62
EV / Sales	4.30
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	42.76

Financial Position

The company has a current ratio of 6.33, with a Debt / Equity ratio of 2.95.

Current Ratio	6.33
Quick Ratio	6.31
Debt / Equity	2.95
Debt / EBITDA	39.77
Debt / FCF	5.18
Interest Coverage	-0.70

Financial Efficiency

Return on equity (ROE) is -28.25% and return on invested capital (ROIC) is -1.32%.

Return on Equity (ROE)	-28.25%
Return on Assets (ROA)	-1.02%
Return on Invested Capital (ROIC)	-1.32%
Return on Capital Employed (ROCE)	-1.83%
Revenue Per Employee	759,687
Profits Per Employee	-44,373
Employee Count	30
Asset Turnover	1.08
Inventory Turnover	39.77

Taxes

In the past 12 months, Read-Gene has paid 439,389 in taxes.

Income Tax	439,389
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +12.00% in the last 52 weeks. The beta is 0.75, so Read-Gene's price volatility has been lower than the market average.

Beta (5Y)	0.75
52-Week Price Change	+12.00%
50-Day Moving Average	5.97
200-Day Moving Average	5.13
Relative Strength Index (RSI)	28.37
Average Volume (20 Days)	606

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Read-Gene had revenue of PLN 15.19 million and -887,457 in losses. Loss per share was -0.08.

Revenue	15.19M
Gross Profit	14.07M
Operating Income	-229,902
Pretax Income	-448,068
Net Income	-887,457
EBITDA	198,860
EBIT	-229,902
Loss Per Share	-0.08

Full Income Statement

Balance Sheet

The company has 5.29 million in cash and 7.91 million in debt, giving a net cash position of -2.61 million or -0.22 per share.

Cash & Cash Equivalents	5.29M
Total Debt	7.91M
Net Cash	-2.61M
Net Cash Per Share	-0.22
Equity (Book Value)	2.68M
Book Value Per Share	0.23
Working Capital	6.91M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 1.98 million and capital expenditures -453,215, giving a free cash flow of 1.53 million.

Operating Cash Flow	1.98M
Capital Expenditures	-453,215
Free Cash Flow	1.53M
FCF Per Share	0.13

Full Cash Flow Statement

Margins

Gross margin is 92.63%, with operating and profit margins of -1.51% and -5.84%.

Gross Margin	92.63%
Operating Margin	-1.51%
Pretax Margin	-2.95%
Profit Margin	-5.84%
EBITDA Margin	1.31%
EBIT Margin	-1.51%
FCF Margin	10.06%

Dividends & Yields

Read-Gene does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	-1.41%
FCF Yield	2.44%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Read-Gene has an Altman Z-Score of 4.41 and a Piotroski F-Score of 3.

Altman Z-Score	4.41
Piotroski F-Score	3